Attempt with oral immunobiotherapy (broncho-vaxom) and immunochemotherapy (broncho-vaxom + neomycin) for the elimination of bacteria in symptom-free "other Salmonella" carriers.
Forty-five symptomless "other Salmonella" carriers were treated; stool became negative for Salmonella in 22 of the 25 patients treated with Broncho-Vaxom (88%) and in 16 of the 20 patients treated with Broncho-Vaxom + Neomycin (80%) (who had discharged Salmonella for not longer than one month previously). This result is very favourable when compared to data of references of thoroughly controlled patients according to which 69% was the highest rate of bacterial negativity obtained in the treated patients who discharged "other Salmonellas" for not longer than 1 month. The stool of all 10 patients admitted as symptomless carriers of "other Salmonellas" became negative for bacteria in response to the mentioned therapy (in 6 cases of Group I, and 4 cases of Group II). Treatment was unsuccessful primarily in chronic alcohol addicts and toxicosis cases (13%). The unresponsiveness of the two patients suffering from cholelithiasis and excreting also "other Salmonella" with the bile deserves attention. In such cases the positivity of the bile for Salmonella was a reason for exclusion from the study. Further studies (completed with immunological data) are required to assess the value of Broncho-Vaxom immunobiotherapy, and Broncho-Vaxom + Neomycin immunotherapy.
Münnich
D
D
Dalmi
L
L
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001419:Bacteria; D002457:Cell Extracts; D004359:Drug Therapy, Combination; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007422:Intestines / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D012475:Salmonella / Q000187:drug effects* / Q000302:isolation & purification; D012712:Serum Globulins / Q000032:analysis; D000095983:Bacterial Lysates
D000276:Adjuvants, Immunologic; D002457:Cell Extracts; D007070:Immunoglobulin A; D009355:Neomycin; D012712:Serum Globulins; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates